tirzepatide off fda shortage list news october 18 2025 has announced that the of # tirzepatide, the ingredient in The FDA Wins. The OFA

Survodutide side effects (Phase 2 data) Nausea: 56% of participants Vomiting: 27% Diarrhea: 22% Constipation: 21% Discontinuation due to adverse events: 24.6% Serious adverse events: 4.2% In the MASH trial, rates were even higher: nausea 66%, diarrhea 49%, vomiting 41%

The Cortisol-Aware GLP-1 Plan: A Practical Playbook Nine evidence-backed moves that stack with your GLP-1 instead of against it

Between 78% and 84% of those on the 10 mg or 15 mg dose lost at least 10% of their body weight

Eden Healths GLP-1 program is currently paused for new patients

Even without visible signs, peptides stored above recommended temperatures or for longer than 28 days post-reconstitution may have lost significant potency